Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2020 Earnings Results

Crinetics Pharmaceuticals Misses on EPS, Stock Up 5.01%

The earnings report shows that Crinetics Pharmaceuticals missed expectations on EPS, which may raise concerns among investors. However, the stock reacted positively, increasing by 5.01%, likely due to management's focus on their drug development pipeline. Investors may be encouraged by the company's long-term strategy despite the short-term EPS miss.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.71	N/A	-13.06%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed a cautious optimism about the future, focusing on their drug development initiatives. They acknowledged the EPS miss but reiterated their strategic goals.

Management highlighted ongoing efforts in drug development despite the EPS miss.

They emphasized their commitment to advancing their pipeline.

Crinetics Pharmaceuticals Misses on EPS, Stock Up 5.01%

Key numbers

Management commentary

Crinetics Pharmaceuticals, Inc.

More earnings this week

Crinetics Pharmaceuticals Misses on EPS, Stock Up 5.01%

Key numbers

Management commentary